| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 85 0 |
 SM ISO690:2012SAPOJNIC, Nadejda, CARAUSH, A., ROIBU, Călin, CARAUSH, M., MOSCALU, Vitalie. Evolution of LV remodeling geometry and insulin resistance indices under conventional active medication on RAS: ramipril and eprosartan. In: European Journal of Heart Failure, 2019, vol. 21, supl. nr. 1, pp. 202-203. ISSN 1388-9842. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
  European Journal of Heart Failure |
||||||
| Volumul 21, Supliment nr. 1 / 2019 / ISSN 1388-9842 /ISSNe 1879-0844 | ||||||
|
||||||
| Pag. 202-203 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
In hypertensive patients, LVH and insulin resistance (IR) often coexist, amplifying development of TOD and HF. Therapeutic strategies should aim BP values, LVH , IR and RAS inhibitors would be "drug of choice" for such combinations. Objective: To compare the effects of an ARB-based regimen with eprosartan and ACEI ramipril on LVH and IR in hypertensives with preserved EF. Methods: 101 hypertensives (48,51% of men; 51,1±0,71 yrs) with LVH and IR were randomly assigned to ramipril (R-gr; n=56, mean dose=15,3mg±1,2 mg/d) or eprosartan (E-gr; n=45, mean dose=850±12,4 mg/d). ABPM, TTE, and HOMAIR were performed (baseline, 6, 12- months). LVMI> 95 g/m2 in women and >115 g/m2 in men identified LVH. Relative wall thickness (RWT >0.42) categorize geometry of Evolution of LV remodeling and HOMA IR. LV remodeling. To define IR was used HOMAIR levels > 2.5. Results: LV remodeling indices have a beneficial evolution in both study groups, but more significant (p<0.05) in the E-gr. After 12 months, number of patients in E-gr, who expressed normal pattern of LV geometry, appears to be almost twice higher compared to R-gr. Both therapeutic regimens have gradually improved HOMAIR values ( p<0.001), but with greater reduction in Egr (p<0.001) (Tab.1) Conclusion: Both drug-regiment progressively improve hypertensive LV geometry and IR indices, but with greater efficiency in the Eprosartan-medicated arm, proba-bly due to additional sympatholytic effect of its moiety. |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Sapojnic, N.C.</creatorName> <affiliation>IMSP Institutul de Cardiologie, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Carauş, A.P.</creatorName> <affiliation>IMSP Institutul de Cardiologie, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Roibu, C.</creatorName> <affiliation>Institutul de Neurologie si Neurochirurgie ”Diomid Gherman”, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Carauş, M.</creatorName> <affiliation>Spitalul Clinic de Recuperare, Iaşi, România</affiliation> </creator> <creator> <creatorName>Moscalu, V.D.</creatorName> <affiliation>IMSP Institutul de Cardiologie, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='en'>Evolution of LV remodeling geometry and insulin resistance indices under conventional active medication on RAS: ramipril and eprosartan</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2019</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1388-9842</relatedIdentifier> <dates> <date dateType='Issued'>2019-03-04</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>In hypertensive patients, LVH and insulin resistance (IR) often coexist, amplifying development of TOD and HF. Therapeutic strategies should aim BP values, LVH , IR and RAS inhibitors would be "drug of choice" for such combinations. Objective: To compare the effects of an ARB-based regimen with eprosartan and ACEI ramipril on LVH and IR in hypertensives with preserved EF. Methods: 101 hypertensives (48,51% of men; 51,1±0,71 yrs) with LVH and IR were randomly assigned to ramipril (R-gr; n=56, mean dose=15,3mg±1,2 mg/d) or eprosartan (E-gr; n=45, mean dose=850±12,4 mg/d). ABPM, TTE, and HOMAIR were performed (baseline, 6, 12- months). LVMI> 95 g/m2 in women and >115 g/m2 in men identified LVH. Relative wall thickness (RWT >0.42) categorize geometry of Evolution of LV remodeling and HOMA IR. LV remodeling. To define IR was used HOMAIR levels > 2.5. Results: LV remodeling indices have a beneficial evolution in both study groups, but more significant (p<0.05) in the E-gr. After 12 months, number of patients in E-gr, who expressed normal pattern of LV geometry, appears to be almost twice higher compared to R-gr. Both therapeutic regimens have gradually improved HOMAIR values ( p<0.001), but with greater reduction in Egr (p<0.001) (Tab.1) Conclusion: Both drug-regiment progressively improve hypertensive LV geometry and IR indices, but with greater efficiency in the Eprosartan-medicated arm, proba-bly due to additional sympatholytic effect of its moiety.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>
|
|
|
